Cargando…

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors might have pleiotropic effects because receptors for incretin exist in various tissues, including liver. We examined whether DPP-4 inhibitors affect liver function in patients with type 2 diabetes. MATERIAL/METHODS: A retrospective review of 459...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanazawa, Ippei, Tanaka, Ken-ichiro, Sugimoto, Toshitsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173801/ https://www.ncbi.nlm.nih.gov/pubmed/25228119 http://dx.doi.org/10.12659/MSM.890989

Ejemplares similares

Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus
por: Miyake, Hitomi, et al.
Publicado: (2019)

Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2018)

Diabetes Mellitus-induced Bone Fragility
por: Kanazawa, Ippei, et al.
Publicado: (2018)

Nerve conduction velocity is negatively associated with intima-media thickness and brachial-ankle pulse wave velocity in men with type 2 diabetes mellitus
por: Tanaka, Sayuri, et al.
Publicado: (2018)

Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus
por: Miyake, Hitomi, et al.
Publicado: (2018)

Phloretin Promotes Adipogenesis via Mitogen-Activated Protein Kinase Pathways in Mouse Marrow Stromal ST2 Cells
por: Takeno, Ayumu, et al.
Publicado: (2018)

Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway
por: Takeno, Ayumu, et al.
Publicado: (2019)

Which Is a Better Skeletal Muscle Mass Index for the Evaluation of Physical Abilities: The Present Height or Maximum Height?
por: Tanaka, Ken-ichiro, et al.
Publicado: (2020)

Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women
por: Miyake, Hitomi, et al.
Publicado: (2017)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2011)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
por: Thomas, Merlin C., et al.
Publicado: (2016)

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Wang, Qixian, et al.
Publicado: (2018)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
por: Bae, Ji Cheol
Publicado: (2022)

Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2016)

The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
por: Makrilakis, Konstantinos
Publicado: (2019)

Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
por: Mu, Liying, et al.
Publicado: (2022)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
por: Farr, Amanda M., et al.
Publicado: (2014)

Assessing Scientific Soundness and Translational Value of Animal Studies on DPP4 Inhibitors for Treating Type 2 Diabetes Mellitus
por: Franco, Nuno Henrique, et al.
Publicado: (2021)

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?
por: Erol, Rumeysa Selvinaz, et al.
Publicado: (2022)

Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects
por: Ahmed, Radwan H., et al.
Publicado: (2016)

Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum
por: Dong, Yan-Jun, et al.
Publicado: (2017)

DPP4 Gene Polymorphism Associates With Type 2 Diabetes Mellitus in Older Adults
por: Alves, Elisa, et al.
Publicado: (2020)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity
por: Lee, Jae-Geun, et al.
Publicado: (2011)

Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells
por: Kanazawa, Ippei, et al.
Publicado: (2007)

Effects of DPP4 Inhibitors on Renal Outcomes in Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Dalui, Saikat K., et al.
Publicado: (2021)

Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
por: Takeno, Ayumu, et al.
Publicado: (2019)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus
por: Yamamoto, Masahiro, et al.
Publicado: (2019)

Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats
por: Miranda, Pedro Henrique de A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_arv7egtm7um3c7tdllnrbt6h1j